Response's flu test:
This article was originally published in Clinica
Response Biomedical has received US 510(k) clearance of its influenza A and B diagnostic, Flu A+B test. The rapid, point-of-care test will run on the Vancouver, Canada-based firm's new RAMP analyser platform, the RAMP 200. It will be marketed and sold exclusively worldwide by 3M Health Care as the 3M Rapid Detection Flu A+B Test. Response filed the 510(k) application in June 2007 (see Clinica No 1260, p 22). 3M Health Care plans to launch the test before the 2008-09 flu season in certain markets, and added it would be the first product sold in the US as part of its medical diagnostics platform.
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
COVID-19: Medtronic Shares Ventilator Specs Amid Multi-Industry Efforts To Increase Ventilator Production
Medtronic shares an open-source design for its ventilator to help mitigate the nation’s ventilator shortage for COVID-19 patients.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.